ESPR Esperion Therapeutics Inc

Price (delayed)

$6.67

Market cap

$420.25M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.75

Enterprise value

$746.89M

Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make ...

Highlights
The company's gross profit has shrunk by 70% YoY but it rose by 9% QoQ
The quick ratio has soared by 66% YoY but it has contracted by 18% from the previous quarter
The gross margin has contracted by 20% YoY and by 4.6% from the previous quarter
Esperion Therapeutics's debt has increased by 15% YoY

Key stats

What are the main financial stats of ESPR
Market
Shares outstanding
63.01M
Market cap
$420.25M
Enterprise value
$746.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.36
Earnings
Revenue
$89.31M
EBIT
-$182.61M
EBITDA
-$182M
Free cash flow
-$213.73M
Per share
EPS
-$6.75
Free cash flow per share
-$3.51
Book value per share
-$3.96
Revenue per share
$1.47
TBVPS
$5.62
Balance sheet
Total assets
$342.85M
Total liabilities
$591.89M
Debt
$527M
Equity
-$249.04M
Working capital
$211.73M
Liquidity
Debt to equity
-2.12
Current ratio
3.68
Quick ratio
3.71
Net debt/EBITDA
-1.79
Margins
EBITDA margin
-203.8%
Gross margin
78.1%
Net margin
-263%
Operating margin
-209.3%
Efficiency
Return on assets
-76.4%
Return on equity
N/A
Return on invested capital
-33.7%
Return on capital employed
-69.2%
Return on sales
-204.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ESPR stock price

How has the Esperion Therapeutics stock price performed over time
Intraday
6.38%
1 week
18.05%
1 month
15%
1 year
-68.43%
YTD
33.4%
QTD
43.75%

Financial performance

How have Esperion Therapeutics's revenue and profit performed over time
Revenue
$89.31M
Gross profit
$69.75M
Operating income
-$186.9M
Net income
-$234.9M
Gross margin
78.1%
Net margin
-263%
The company's gross profit has shrunk by 70% YoY but it rose by 9% QoQ
ESPR's revenue has dropped by 62% year-on-year but it is up by 14% since the previous quarter
The net income has plunged by 50% YoY but it has grown by 13% from the previous quarter
The company's operating income fell by 44% YoY but it rose by 18% QoQ

Growth

What is Esperion Therapeutics's growth rate over time

Valuation

What is Esperion Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
4.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.36
Esperion Therapeutics's EPS has increased by 27% QoQ but it has decreased by 15% YoY
The equity has decreased by 26% QoQ but it has increased by 8% YoY
ESPR's revenue has dropped by 62% year-on-year but it is up by 14% since the previous quarter
The price to sales (P/S) is 7% lower than the last 4 quarters average of 4.6

Efficiency

How efficient is Esperion Therapeutics business performance
The return on assets has declined by 48% year-on-year but it rose by 17% since the previous quarter
The return on invested capital has grown by 35% year-on-year and by 24% since the previous quarter
Esperion Therapeutics's return on sales has increased by 28% QoQ

Dividends

What is ESPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ESPR.

Financial health

How did Esperion Therapeutics financials performed over time
The total assets is 42% less than the total liabilities
The quick ratio has soared by 66% YoY but it has contracted by 18% from the previous quarter
The company's current ratio rose by 32% YoY but it fell by 18% QoQ
The equity has decreased by 26% QoQ but it has increased by 8% YoY
ESPR's debt to equity is down by 25% year-on-year but it is up by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.